The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $44.02 down -0.34% from its previous closing price of $44.17. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 0.82 million shares were traded.
Ratios:
For a deeper understanding of MoonLake Immunotherapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $67.
Goldman Upgraded its Neutral to Buy on January 17, 2025, whereas the target price for the stock was revised from $62 to $82.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 04 ’24 when BVF PARTNERS L P/IL sold 2,000,000 shares for $50.00 per share. The transaction valued at 100,003,200 led to the insider holds 1,287,768 shares of the business.
Sturge Simon sold 171,000 shares of MLTX for $9,186,120 on Oct 04 ’24. The Director now owns 171,980 shares after completing the transaction at $53.72 per share.
Stock Price History:
Over the past 52 weeks, MLTX has reached a high of $58.26, while it has fallen to a 52-week low of $31.42. The 50-Day Moving Average of the stock is 10.49%, while the 200-Day Moving Average is calculated to be -3.45%.
Shares Statistics:
A total of 63.47M shares are outstanding, with a floating share count of 52.94M. Insiders hold about 16.60% of the company’s shares, while institutions hold 94.66% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.72 and low estimates of -$0.83.
Analysts are recommending an EPS of between -$2.72 and -$3.14 for the fiscal current year, implying an average EPS of -$2.92. EPS for the following year is -$3.54, with 8.0 analysts recommending between -$1.83 and -$4.07.
